Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Appointed director
Quarterly results
|
|
Edesa Biotech, Inc. (SBOT)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/12/2023 |
8-K
| Quarterly results |
| 10/11/2023 |
8-K
| Quarterly results |
| 08/09/2023 |
8-K
| Quarterly results |
| 05/24/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 05/11/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 03/27/2023 |
8-K
| Quarterly results |
| 03/13/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
| 02/10/2023 |
8-K
| Quarterly results |
| 12/16/2022 |
8-K
| Quarterly results |
| 11/03/2022 |
8-K
| Quarterly results |
| 08/12/2022 |
8-K
| Quarterly results |
| 05/19/2022 |
8-K
| Quarterly results |
| 05/13/2022 |
8-K
| Quarterly results |
| 03/29/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 03/23/2022 |
8-K
| Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Unregistered Sales of Equity Secu...|
Docs:
|
"PRE-FUNDED COMMON SHARE PURCHASE WARRANT EDESA Biotech, inc. Warrant Shares: _______ Initial Exercise Date: March __, 2022 THIS PRE-FUNDED COMMON SHARE PURCHASE WARRANT certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above and on or prior to 5:00 p.m. until this Warrant is exercised in full but not thereafter, to subscribe for and purchase from Edesa Biotech, Inc., a corporation incorporated under the laws of British Columbia, Canada , up to ______ shares of the Company’ s Common Shares. The purchase price of one Common Share under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1 . D...",
"COMMON SHARE PURCHASE WARRANT EDESA Biotech, inc. Warrant Shares: _______ Initial Exercise Date: March __, 2022 THIS COMMON SHARE PURCHASE WARRANT certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above and on or prior to 5:00 p.m. on ________ 1 but not thereafter, to subscribe for and purchase from Edesa Biotech, Inc., a corporation incorporated under the laws of British Columbia, Canada , up to ______ shares of the Company’ s Common Shares. The purchase price of one Common Share under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1 . Definitions . Capitalized terms used and not othe...",
"COMMON SHARE PURCHASE WARRANT EDESA Biotech, inc. Warrant Shares: _______ Initial Exercise Date: March 24, 2022 THIS COMMON SHARE PURCHASE WARRANT certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above and on or prior to 5:00 p.m. on March 21, 2027 but not thereafter, to subscribe for and purchase from Edesa Biotech, Inc., a corporation incorporated under the laws of British Columbia, Canada , up to ______ shares of the Company’ s Common Shares. The purchase price of one Common Share under this Warrant shall be equal to the Exercise Price, as defined in Section 2. This Warrant is being issued pursuant to that certain eng...",
"Markham, ON L3R 5H6",
"Markham, Ontario, Canada L3R 5H6",
"SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement is dated as of March 21, 2022, between Edesa Biotech, Inc., a company incorporated under the laws of British Columbia, Canada , and each purchaser identified on the signature pages hereto . WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to an effective registration statement under the Securities Act as to the Shares, the Pre-Funded Warrants and Pre-Funded Warrant Shares and an exemption from the registration requirements of Section 5 of the Securities Act contained in Section 4 thereof and/or Regulation D thereunder as to the Common Warrants, the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, secur...",
"Edesa Biotech Announces $10.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules TORONTO, ON / ACCESSWIRE / March 22, 2022 /" |
|
| 03/04/2022 |
8-K
| Quarterly results |
| 03/04/2022 |
8-K
| Quarterly results |
| 03/02/2022 |
8-K
| Quarterly results |
| 02/14/2022 |
8-K
| Quarterly results |
| 12/28/2021 |
8-K
| Quarterly results |
| 11/22/2021 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
| 08/13/2021 |
8-K
| Quarterly results |
| 05/14/2021 |
8-K
| Quarterly results |
| 04/23/2021 |
8-K
| Quarterly results |
| 03/22/2021 |
8-K
| Quarterly results |
| 02/26/2021 |
8-K/A
| Quarterly results |
| 02/26/2021 |
8-K
| Quarterly results |
| 02/16/2021 |
8-K
| Quarterly results |
| 02/03/2021 |
8-K
| Quarterly results |
| 12/07/2020 |
8-K
| Quarterly results |
| 09/28/2020 |
8-K
| Quarterly results |
| 09/28/2020 |
8-K
| Quarterly results |
| 08/12/2020 |
8-K
| Quarterly results |
| 05/15/2020 |
8-K
| Quarterly results |
|
|
|